Neoadjuvant PD-1-Based Immunotherapy in Localized dMMR/MSI-H Colorectal Cancer: A Systematic Review and Arm-Based Meta-Analysis
Cancers · 29.07.2026 · 18 (15) · 2436
DOI: 10.3390/cancers18152436 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 29.07.2026. Verfasst von Mohammed M Alruwaili und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory Technology, College of Applied Medical Sciences, Northern Border University, Arar 91431, Saudi Arabia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Northern Border University.
Abstract (Originalsprache)
Background/Objectives: Deficient mismatch repair (dMMR) and microsatellite instability-high (MSI-H) colorectal cancer (CRC) are highly sensitive to immune checkpoint blockade. We evaluated the efficacy, safety, and clinical maturity of neoadjuvant PD-1-based immunotherapy in localized disease.
Methods
This PRISMA-compliant systematic review included prospective studies of neoadjuvant PD-1-based therapy in localized dMMR/MSI-H CRC. Proportions were pooled on the logit scale using inverse-variance random-effects models with the Paule–Mandel estimator. Pathologic complete response (pCR) was the primary outcome; major pathologic response (MPR), immune-related adverse events (irAEs), surgery, clinical complete response (cCR), organ preservation, and long-term outcomes were secondary outcomes.
Results
Five prospective studies were included. Four studies, comprising 305 treated patients and 292 pathologically evaluable patients, contributed five treatment arms to the quantitative synthesis. The pooled pCR proportion was 0.65 (95% CI, 0.54–0.74), and the pooled MPR proportion was 0.89 (95% CI, 0.79–0.94). Exploratory subgroup analyses suggested higher response proportions with combination regimens, but clinical and methodological differences confounded these predominantly indirect comparisons. Any-grade irAEs occurred in 0.54 (95% CI, 0.36–0.71), whereas grade ≥3 irAEs occurred in 0.06 (95% CI, 0.04–0.10). The pooled surgery proportion was 0.96 (95% CI, 0.86–0.99), although this outcome largely reflected protocol-mandated surgery. cCR and organ preservation were promising in selected rectal-cancer cohorts. Survival and recurrence data were immature and unsuitable for quantitative pooling.
Conclusions
Neoadjuvant PD-1-based immunotherapy is a highly promising investigational strategy for localized dMMR/MSI-H CRC. Nevertheless, predominantly early-phase evidence, indirect comparisons, heterogeneous endpoints, and limited follow-up preclude definitive conclusions regarding routine clinical adoption.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Laboratory Technology, College of Applied Medical Sciences, Northern Border University, Arar 91431, Saudi Arabia.
- Center for Health Research, Northern Border University, Arar 91431, Saudi Arabia.
- Faculty of Medicine, Zagazig University, Zagazig 44519, Egypt.
- Department of Medical Laboratory, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.
- Department of Anatomic Pathology, Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.
- Pathology Department, College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
ORCID-Profile: Mohammed M Alruwaili, Yehia Nabil, Helal G Alanazi, Abdulrahman A Alahmari, Emad Alqassim, Manal S Fawzy
Förderung
- Northern Border University
Zitieren
APA
Alruwaili, M. M., Nabil, Y., Alanazi, Y., Alanazi, H. G., Alahmari, A. A., Alqassim, E., Alsel, B. A., & Fawzy, M. S. (2026). Neoadjuvant PD-1-Based Immunotherapy in Localized dMMR/MSI-H Colorectal Cancer: A Systematic Review and Arm-Based Meta-Analysis. Cancers, 18(15), 2436. https://doi.org/10.3390/cancers18152436
Vancouver
Alruwaili MM, Nabil Y, Alanazi Y, Alanazi HG, Alahmari AA, Alqassim E, et al. Neoadjuvant PD-1-Based Immunotherapy in Localized dMMR/MSI-H Colorectal Cancer: A Systematic Review and Arm-Based Meta-Analysis. Cancers. 2026;18(15):2436. doi:10.3390/cancers18152436
BibTeX
@article{Alruwaili2026,
author = {Alruwaili, Mohammed M and Nabil, Yehia and Alanazi, Yousef and Alanazi, Helal G and Alahmari, Abdulrahman A and Alqassim, Emad and Alsel, Baraah Abu and Fawzy, Manal S},
title = {Neoadjuvant PD-1-Based Immunotherapy in Localized dMMR/MSI-H Colorectal Cancer: A Systematic Review and Arm-Based Meta-Analysis},
journal = {Cancers},
year = {2026},
volume = {18},
number = {15},
pages = {2436},
doi = {10.3390/cancers18152436}
}
EUVIMED